76. HCC systemic therapy 在第三期臨床試驗中，下列何者未納入 main portal vein invasion 進入試驗？
(1) IMbrave 150
(2) REFLECT
(3) KEYNOTE 240
(4) RESORCE
(A) (1)＋(2)
(B) (2)＋(3)
(C) (1)＋(2)＋(3)
(D) (2)

(E) (1)＋(3)

72. 依據 2018 HCC EASL Clinical Practice Guidelines，Local ablation 的敘述下列何者正確？(1) RFA is the standard of care for patients with BCLC 0 and A tumors not suitable for surgery(2) For BCLC-0, RFA in favorable locations can be adopted as first-line therapy(3) Ethanol injection is an option in some cases where RFA is not technically feasible, especially in tumors ＜2 cm(4) For sub-capsular HCCs, the technical success and the risk of complications should be considered when applying RFA(5) Tumor location has highly important consequences on the choice between RFA or surgery(A) (1)＋(2)(B) (1)＋(2)＋(3)(C) (1)＋(2)＋(3)＋(4)(D) (1)＋(2)＋(3)＋(4)＋(5)(E) (1)＋(2)＋(4)

73. 依據 2018 HCC EASL Clinical Practice Guidelines，TACE 的敘述下列何者正確？(1) The indication for TACE should consider tumour burden, underlying liver disease, and performance status(2) Inadequate hepatic function, such as serum bilirubin ＞2 mg/dl, and a tumor burden ＞50% of total liver volume, increase the risk of hepaticdecompensation after TACE(3) Segmental or sub-segmental portal vein tumor invasions are absolute contraindications for TACE(4) Patients with biliary-enteric anastomosis or biliary stent are at higher risk of hepatic abscess by TACE(A) (1)＋(2)(B) (1)＋(2)＋(3)(C) (2)＋(3)＋(4)(D) (1)＋(2)＋(3)＋(4)(E) (1)＋(2)＋(4)

74. 關於 HCC systemic therapy 的敘述下列何者正確？(1) Systemic chemotherapy with doxorubicin or FOLFOX did not demonstrate survival benefits(2) Lenvatinib targets VEGFR1-3; fibroblast growth factor receptor (FGFR1-4);platelet-derived growth factor receptor α, RET, and KIT(3) Cabozantinib is a MET, VEGFR2 and RET inhibitor approved for thyroid,renal cancer and HCC(4) Ramucirumab is a monoclonal antibody targeting VEGFR 1-3(5) Progression-free survival is a composite endpoint that includes two types of variables: death and evidence of radiological progression(A) (1)＋(2)(B) (1)＋(2)＋(3)(C) (2)＋(3)＋(4)(D) (1)＋(2)＋(3)＋(5)(E) (1)＋(2)＋(3)＋(4)＋(5)

75. 依據 2018 AASLD Guidelines for the Treatment of Hepatocellular Carcinoma，下列何者敘述錯誤？(1) The AASLD suggests surveillance using ultrasound (US) and alpha-fetoprotein (AFP) every 6 months(2) The AASLD recommends diagnostic evaluation for HCC with either multiphasic CT or multiphasic MRI because of similar diagnosticperformance characteristics(3) The AASLD suggests that adults with Child-Pugh class A cirrhosis and resectable T1 or T2 HCC undergo resection over radiofrequency ablation(4) The AASLD does not recommend one form of liver-directed therapy over another for the purposes of bridging to liver transplantation for patientswithin Milan criteria(A) (1)(B) (2)(C) (3)(D) (4)(E) (1)＋(3)

77. 關於 HCC systemic therapy，依據 phase 3 clinical trials 的結果，下列敘述何者正確？(1) Atezolizumab + Bevacizumab 在一線 systemic therapy，objective response rate (ORR) ＞25%(2) Lenvatinib 在一線 systemic therapy，objective response rate (ORR) ＞20%(3) Sorafenib 在一線 systemic therapy，最好的 median overall survival 可以超過 14 個月(4) Median progression-free survival (PFS)，lenvatinib 不輸於 Atezolizumab +Bevacizumab(A) (1)(B) (1)＋(2)(C) (1)＋(2)＋(3)(D) (1)＋(2)＋(3)＋(4)(E) (1)＋(3)

78. 關於 HCC radioembolization(TARE)or Selective internal radiation therapy(SIRT)的敘述，下列何者正確？(1) There was no significant difference in OS between sorafenib and TARE in SIRveNIB and SARAH studies for advanced HCC(2) Current data demonstrate benefit of TARE compared to sorafenib in patients with advanced HCC(3) Compared to TACE, SIRT provides significantly longer time to progression and better tumor control, but it does not provide longer survival(4) SIRT might prepare or select patients for surgery as it induces substantial hypertrophy in the liver lobe contralateral to the target(A) (2)(B) (1)＋(2)＋(3)(C) (2)＋(3)＋(4)(D) (1)＋(2)＋(3)＋(4)(E) (1)＋(3)＋(4)

79. 關於 Cholangiocarcinoma(CCA)的敘述，下列何者正確？(1) Adjuvant chemotherapy with capecitabine for 6 months after surgical resection with curative intent is recommended for intrahepatic CCA(2) Liver transplantation is a potentially curative option for intrahepatic and perihilar CCA(3) FOLFOX (folinic acid, fluorouracil and oxaliplatin) can be recommended as second- line standard of care chemotherapy(4) Combination of cisplatin and gemcitabine is the standard of care for patients with unresected tumors(5) Cirrhosis is one of the risk factors of intrahepatic CCA(A) (2)＋(4)(B) (1)＋(2)＋(3)＋(4)(C) (2)＋(3)＋(4)(D) (1)＋(2)＋(3)＋(4)＋(5)(E) (1)＋(2)＋(4)

80. 關於 HCC image diagnostic performance 的敘述，下列何者正確？(1) Dynamic plus hepatobiliary phase MRI had a higher sensitivity and negative predictive value than multiphasic CT and dynamic phase MRI alone(2) Gadoxetic acid is unique in that approximately 50% of the administrated dose is taken up by the hepatocytes and excreted into the bile ducts(3) On gadoxetic acid enhanced MRI, hyper-intensity on hepatobiliary phase is regarded as an ancillary finding favoring malignancy(4) Gadoxetic acid-enhanced MRI has a higher sensitivity for detecting nodules that are either HCC not displaying the typical features of imaging hallmarksor high-grade dysplastic nodules(A) (2)(B) (1)＋(2)＋(4)(C) (1)＋(2)(D) (1)＋(2)＋(3)＋(4)(E) (2)＋(4)

81. 下列何者會抑制膽囊的收縮？(A)迷走神經(B)激膽囊素(cholecystokinin)(C)胰泌素(secretin)(D)胃泌素(gastrin)(E)腸動素(motilin)

82. 下列何者不是 Rome IV criteria(Clinical criteria for diagnosis of functional gallbladder and sphincter of Oddi disorders)中所描述的膽道型疼痛(biliarypain)？(1)疼痛位於上腹部或右上腹(2)每次疼痛大於 30 分鐘(3)反覆發作但是不定間隔時間(4)嚴重疼痛影響日常生活，或需求助急診(5)疼痛常伴隨腹瀉(A) (2)＋(4)(B) (1)＋(3)(C) (4)(D) (5)(E) (2)＋(5)